Patents by Inventor Ning Xi

Ning Xi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150342945
    Abstract: The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Application
    Filed: August 12, 2015
    Publication date: December 3, 2015
    Applicants: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventor: Ning XI
  • Publication number: 20150299219
    Abstract: The present invention provides substituted bicyclic pyrazolone compounds, which are used to inhibit or modulate the activity of receptor tyrosine kinases, especially Axl, Mer, c-Met and Ron. The invention also provides pharmaceutical compositions comprising the compound disclosed herein, and a method of preventing, treating or lessening the severity of a proliferative disorder in a patient with the compounds or the pharmaceutical compositions disclosed herein.
    Type: Application
    Filed: April 16, 2015
    Publication date: October 22, 2015
    Applicants: Calitor Sciences, LLC, Sunshine Lake Pharma Co., Ltd.
    Inventors: Ning Xi, Yanjun Wu
  • Publication number: 20150274747
    Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.
    Type: Application
    Filed: March 27, 2015
    Publication date: October 1, 2015
    Applicants: Calitor Sciences, LLC, Sunshine Lake Pharma Co., Ltd.
    Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Weilong Dai, Tingjin Wang
  • Publication number: 20150274705
    Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.
    Type: Application
    Filed: March 27, 2015
    Publication date: October 1, 2015
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLC
    Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Tao Zhang, Yanjun Wu
  • Publication number: 20150274704
    Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.
    Type: Application
    Filed: March 27, 2015
    Publication date: October 1, 2015
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLC
    Inventors: Ning Xi, Minxiong Li, Haiyang Hu, Weilong Dai
  • Patent number: 9133162
    Abstract: The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: September 15, 2015
    Assignees: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLC
    Inventor: Ning Xi
  • Patent number: 9066954
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: June 30, 2015
    Assignee: Amgen Inc.
    Inventors: Brian K. Albrecht, David Bauer, Steven Bellon, Christiane M. Bode, Shon Booker, Alessandro Boezio, Deborah Choquette, Derin D'Amico, Jean-Christophe Harmange, Satoko Hirai, Randall W. Hungate, Tae-Seong Kim, Richard T. Lewis, Longbin Liu, Julia W. Lohman, Mark H. Norman, Michele Potashman, Aaron C. Siegmund, Stephanie K. Springer, Markian Stec, Ning Xi, Kevin Yang
  • Publication number: 20150141463
    Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Application
    Filed: January 20, 2015
    Publication date: May 21, 2015
    Applicants: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
  • Patent number: 9004201
    Abstract: A jumping robot is provided. In another aspect, a jumping robot weighs less than 50 grams, jumps at least 20 cm high and has a maximum linear dimension of 10 cm. A further aspect provides a robot that employs an electromagnetic actuator that actuates at least two of: jumping, steering, self-righting, and/or mid-air orientation control.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 14, 2015
    Assignee: Board of Trustees of Michigan State University
    Inventors: Ning Xi, Jianguo Zhao, Bingtuan Gao, Jing Xu, Matt Mutka, Li Xiao
  • Publication number: 20150087658
    Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.
    Type: Application
    Filed: September 17, 2014
    Publication date: March 26, 2015
    Applicants: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Liang Wang, Tingjin Wang
  • Publication number: 20150087663
    Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not limited to leukemias and solid tumors, in mammals, especially humans.
    Type: Application
    Filed: September 17, 2014
    Publication date: March 26, 2015
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLC
    Inventors: Ning Xi, Liang Wang, Zuping Wu, Xuejin Feng, Yanjun Wu
  • Patent number: 8975282
    Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: March 10, 2015
    Assignees: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLC
    Inventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
  • Patent number: 8969388
    Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: March 3, 2015
    Assignees: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLC
    Inventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
  • Publication number: 20150050239
    Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Application
    Filed: July 19, 2013
    Publication date: February 19, 2015
    Applicants: Calitor Sciences, LLC, Sunshine Lake Pharma Co., Ltd.
    Inventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
  • Publication number: 20150042764
    Abstract: A method is provided for constructing a three-dimensional hyperspectral image using compressive sensing. The method includes: configuring on/off state of each mirror in an array of micromirrors in accordance with a pattern; capturing image data of a scene from a first point of view using a first photodetector; and capturing image data of the scene from second point of view using a second photodetector, where second point of view differs from the first point of view. The steps are repeated to obtain a series of measurement samples, where the array of micromirrors is configured in accordance with a pattern that differs amongst each measurement samples. By choosing different photodetectors with different band gap nanomaterials, the first and second photodetectors detects photons in the electromagnetic spectrum. As a result, the three-dimensional image also carry the spectrum information of the scene.
    Type: Application
    Filed: August 4, 2014
    Publication date: February 12, 2015
    Inventors: Ning Xi, King Wai Chiu Lai, Hongzhi Chen, LiangLiang Chen, Bo Song
  • Publication number: 20150042781
    Abstract: Compressive sensing based video rate imaging techniques are presented. Rather than scan the entire image, the imaging system only scans part of the topography of the sample as a compressed scan. After the data has been collected, an algorithm for image reconstruction is applied for recovering the image. Because compressive sensing is used, the imaging rate is increased from several minutes per frame to seconds per frame. Non-vector space control techniques are also presented. No-vector space control use image or compressive data as the input and feedback to generate a closed-loop motion control. Compressive sensing technique provides an efficient data reduction method to retain the essential information in the original image. The non-vector space control method can be used as motion control method with compressive feedback without or with noise.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 12, 2015
    Applicant: Board of Trustees of Michigan State University
    Inventors: Ning Xi, Bo Song, Jianguo Zhao, Wai Chiu King Lai
  • Publication number: 20150037280
    Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Application
    Filed: July 19, 2013
    Publication date: February 5, 2015
    Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLC
    Inventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
  • Publication number: 20140234254
    Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Application
    Filed: February 15, 2014
    Publication date: August 21, 2014
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLC
    Inventor: Ning Xi
  • Publication number: 20140134133
    Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Application
    Filed: November 10, 2013
    Publication date: May 15, 2014
    Applicants: Calitor Sciences, LLC
    Inventor: Ning Xi
  • Patent number: 8685983
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: April 1, 2014
    Assignee: Amgen Inc.
    Inventors: Tae-Seong Kim, David Bauer, Steven Bellon, Alessadro Boezio, Shon Booker, Deborah Choquette, Derin C. D'Amico, Noel D'Angelo, Celia Dominguez, Ingrid M. Fellows, Julie Germain, Russell Graceffa, Jean-Christophe Harmange, Satoko Hirai, Daniel La, Matthew Lee, Longbin Liu, Mark H. Norman, Michele Potashman, Philip Roveto, Aaron C. Siegmund, Ning Xi, Kevin Yang